Mononuclear Cells

Phase 2Cell therapy

NNational University of Malaysia

Mononuclear Cells is one of 74 biologic programs targeting Osteonecrosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteonecrosisActive, not recruiting

LeukemiaNot yet recruiting

RefractoryRecruiting

GastritisActive, not recruiting

OsteonecrosisPreclinical

Active, not recruiting

LeukemiaPhase 2

Not yet recruiting

RefractoryPreclinical

Recruiting

GastritisPreclinical

Active, not recruiting

Competition

Competitive Landscape

108 competitors in Leukemia

#DrugCompanyPhaseTrials

Cytosar

Teva

Phase 3

53 2

Trexall

Jazz Pharmaceuticals

Phase 3

30 3

Fludara

Sanofi

Phase 3

20 4

Rituxan

Roche

Phase 3

16 5

Cytoxan

BBaxter Healthcare Corporation

Phase 3

56 6

Adriamycin

Pfizer

Phase 3

11 7

Oncovin

Eli Lilly

Phase 3

10 8

Decadron

AAspen Global Incorporated

Phase 3

23 9

Vepesid

AAvyxa

Phase 3

23 10

Mesnex

BBaxter Healthcare Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Not yet recruiting

Leukemia

NCT07698080

Clinical

Trials by Indication[1]

Osteonecrosis1 trial

Mononuclear Cells, Platelets and Zoledronic Acid for Preventing Collapse of the Femoral Head in Osteonecrosis

Unknown status·—·N/A·NCT02721940·100 enrolled

Ischemia1 trial

Intramuscular Mononuclear Cells and Mesenchymal Stem Cells Transplantation to Treat Chronic Critical Limb Ischemia

Unknown status·NNational University of Malaysia·Phase 2·NCT01456819·50 enrolled

Gastritis1 trial

Clinical Study of Umbilical Cord Blood Mononuclear Cell Therapy for the Treatment of Chronic Atrophic Gastritis

Active, not recruiting·SShandong Provincial Hospital·N/A·NCT05808010·60 enrolled

Refractory1 trial

Efficacy Evaluation of UCB-MNCs in the Treatment of Refractory Neonatal Diseases

Recruiting·SShandong Qilu Stem Cells Engineering Co., Ltd.·N/A·NCT06427642·120 enrolled

Leukemia1 trial

Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific Antibodies in Haploid Hematopoietic Stem Cell Transplantation: a Prospective, Multicenter Study

Not yet recruiting·HHematology department of the 920th hospital·Phase 2·NCT07698080·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Mononuclear Cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mononuclear Cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mononuclear Cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National University of Malaysia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: NNational University of Malaysia

Mononuclear Cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Osteonecrosis1 trial

Ischemia1 trial

Gastritis1 trial

Refractory1 trial

Leukemia1 trial

References

Drug Info

Quick Facts

Related News